Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Zuzana JustinovaSteven R Goldberg

Abstract

Inhibition of the enzyme fatty acid amide hydrolase (FAAH) counteracts reward-related effects of nicotine in rats, but it has not been tested for this purpose in non-human primates. Therefore, we studied the effects of the first- and second-generation O-arylcarbamate-based FAAH inhibitors, URB597 (cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester) and URB694 (6-hydroxy-[1,1'-biphenyl]-3-yl-cyclohexylcarbamate), in squirrel monkeys. Both FAAH inhibitors: (1) blocked FAAH activity in brain and liver, increasing levels of endogenous ligands for cannabinoid and α-type peroxisome proliferator-activated (PPAR-α) receptors; (2) shifted nicotine self-administration dose-response functions in a manner consistent with reduced nicotine reward; (3) blocked reinstatement of nicotine seeking induced by reexposure to either nicotine priming or nicotine-associated cues; and (4) had no effect on cocaine or food self-administration. The effects of FAAH inhibition on nicotine self-administration and nicotine priming-induced reinstatement were reversed by the PPAR-α antagonist, MK886. Unlike URB597, which was not self-administered by monkeys in an earlier study, URB694 was self-administered at a moderate rate. URB694 self-administration was blocked...Continue Reading

References

Dec 1, 1980·Journal of Neuroscience Methods·G PaxinosP C Emson
Jun 27, 2003·Psychopharmacology·Zuzana JustinovaSteven R Goldberg
Oct 16, 2004·Neuroreport·Bernard Le Foll, Steven R Goldberg
Jul 13, 2006·CNS Drug Reviews·Daniele PiomelliDavid Putman
Oct 5, 2006·Psychopharmacology·Mohini Ranganathan, Deepak Cyril D'Souza
Oct 25, 2007·Journal of Lipid Research·Giuseppe AstaritaDaniele Piomelli
Apr 17, 2008·British Journal of Pharmacology·M SolinasD Piomelli
Apr 22, 2008·Addiction Biology·Fabrício A Moreira, Beat Lutz
May 3, 2008·The Journal of Pharmacology and Experimental Therapeutics·Lisa L MerrittM Imad Damaj
Aug 19, 2008·Addictive Behaviors·John R HughesShelly Naud
Dec 19, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Miriam MelisMarco Pistis
Mar 21, 2009·Psychopharmacology·Bernard Le FollSteven R Goldberg
May 23, 2009·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·K JohanssonM Neovius
Oct 20, 2009·Lancet·Wayne Hall, Louisa Degenhardt
Feb 20, 2010·Current Medicinal Chemistry·M Pistis, M Melis
Dec 24, 2010·British Journal of Pharmacology·Linda A ParkerCheryl L Limebeer
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Kate CahillTim Lancaster
Mar 2, 2011·The British Journal of Psychiatry : the Journal of Mental Science·David TaylorUNKNOWN pharmacology subgroup of the National Institute for Health and Clinical Excellence Guideline Development Group for Depressi
Apr 28, 2011·Addiction Biology·Islam GamaleddinBernard Le Foll
Sep 29, 2011·Frontiers in Behavioral Neuroscience·Claudio ZanettiniSevil Yasar
Mar 29, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leigh V PanlilioSteven R Goldberg
Jun 19, 2012·Life Sciences·Pretal P MuldoonM Imad Damaj
Apr 5, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Miriam MelisMarco Pistis

❮ Previous
Next ❯

Citations

Jan 25, 2016·Psychopharmacology·Charles W SchindlerZuzana Justinova
Sep 17, 2015·Nature Reviews. Neuroscience·Loren H Parsons, Yasmin L Hurd
Nov 13, 2015·Psychopharmacology·Leigh V PanlilioZuzana Justinova
Apr 15, 2016·British Journal of Pharmacology·Saoirse Elizabeth O'Sullivan
Jun 18, 2016·The American Journal of Drug and Alcohol Abuse·Angelique G Brellenthin, Kelli F Koltyn
Aug 13, 2015·Journal of Lipid Research·Yvonne WollankBurkhard Hinz
Aug 2, 2017·International Journal of Molecular Sciences·Gábor Nagy-GróczLászló Vécsei
Sep 7, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Douglas L BoggsMohini Ranganathan
Aug 29, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Leigh V Panlilio, Zuzana Justinova
Jun 28, 2018·Addiction Biology·Maria A De LucaGaetano Di Chiara
Jan 16, 2019·Annals of the New York Academy of Sciences·George R UhlJennifer Cable
Sep 28, 2017·The Journal of Pharmacology and Experimental Therapeutics·Michael Z LeonardBrian D Kangas
Dec 29, 2019·British Journal of Pharmacology·Yi HeZheng-Xiong Xi
May 20, 2020·Expert Opinion on Drug Discovery·Kevin Butler, Bernard Le Foll
Jul 28, 2018·Acta Pharmacologica Sinica·Maria SchermaGianluigi Tanda
Nov 16, 2019·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Angelique G BrellenthinKelli F Koltyn
Jan 17, 2020·European Journal of Medicinal Chemistry·Rati Kailash Prasad Tripathi
Nov 7, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Ju-Tao YuXiao-Ming Meng
Jan 12, 2021·Frontiers in Synaptic Neuroscience·Claudia SaghedduMarco Pistis
Sep 28, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Shivani JaiswalSenthil Raja Ayyannan
May 2, 2021·Pharmacology, Biochemistry, and Behavior·Jenny L WilkersonLance R McMahon
Mar 1, 2019·Molecular Neuropsychiatry·Heath D SchmidtNii A Addy
Nov 7, 2021·Neurotoxicity Research·Karen Jaqueline Paredes-RuizAna Laura Colín-González
Sep 14, 2021·Annual Review of Pharmacology and Toxicology·Daniele Piomelli, Alex Mabou Tagne

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.